Articles From: BioDelivery Sciences Announces Submission of NDA for BUNAVAIL to Biogen Idec and Isis Pharmaceuticals Announce Strategic Collaboration to Advance Treatment of Neurological Disorders


2013/8/1
First buprenorphine naloxone buccal film for the maintenance treatment of opioid dependence RALEIGH, N.C. , Aug.
Sign-up for BioDelivery Sciences Announces Submission of NDA for BUNAVAIL investment picks
Experienced industry veteran augments BDSI's executive management team as company moves toward finalization of its commercial options for BUNAVAIL and explores further business development opportunities RALEIGH, N.C. , Oct.
Sign-up for BioDelivery Sciences Appoints Ernest De Paolantonio as Chief Financial Officer investment picks
2014/2/13
RALEIGH, N.C. , Feb.
Sign-up for BioDelivery Sciences Closes $60 Million Registered Direct Offering investment picks
2014/1/10
BEMA Buprenorphine Phase 3 opioid naive study database lock imminent; triggers $10M milestone payment from Endo Pharmaceuticals BUNAVAIL PDUFA date June 7, 2014 - launch anticipated late third quarter Clonidine Topical Gel Phase 3 program enrollment anticipated to begin first quarter RALEIGH, N.C. , Jan.
Sign-up for BioDelivery Sciences Provides an Update of Anticipated 2014 Milestones investment picks
2014/3/14
BUNAVAIL PDUFA date June 7, 2014; Plans underway for potential Q3 2014 launch Positive results announced for Phase 3 clinical trial of BEMA Buprenorphine in opioid naive patients; results in opioid experienced patients expected mid-2014 Clonidine Topical Gel Phase 3 program initiated; study completion expected by year-end 2014 $60 million equity financing in February solidified balance sheet RALEIGH, N.C. , March 14, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2013 with the U.S. Securities and Exchange Commission and, in connection therewith, is providing a review of BDSI's 2013 financials and achievements as well as an update on business operations and upcoming milestones for 2014.
Sign-up for BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2013 Annual Report investment picks
2013/8/9
BUNAVAIL NDA submitted to FDA; first buccal film to compete in growing opioid dependence marketplace Phase 3 studies for BEMA Buprenorphine for chronic pain on track for completion and data read out by early 2014 Clonidine Topical Gel for Painful Diabetic Neuropathy to initiate Phase 2b study by year-end Cash runway through end of 2014 RALEIGH, N.C. , Aug.
Sign-up for BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Second Quarter 2013 Financials investment picks
2013/11/12
BUNAVAIL NDA Filed; PDUFA date June 7, 2014 Results of initial Phase 3 clinical trial of BEMA Buprenorphine for chronic pain expected early 2014 Clonidine Topical Gel Phase 2B confirmatory trial expected to begin 1Q14 RALEIGH, N.C. , Nov.
Sign-up for BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Third Quarter 2013 Financials investment picks
RALEIGH, N.C. , Nov.
Sign-up for BioDelivery Sciences to Present at the 25th Annual Piper Jaffray Healthcare Conference investment picks
2014/3/5
RALEIGH, N.C. , March 5, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr.
Sign-up for BioDelivery Sciences to Present at the 26th Annual ROTH Conference investment picks
2014/2/28
RALEIGH, N.C. , Feb.
Sign-up for BioDelivery Sciences to Present at the Cowen and Company 34th Annual Health Care Conference investment picks
2013/9/6
RALEIGH, N.C. , Sept.
Sign-up for BioDelivery Sciences to Present at the Stifel Nicolaus 2013 Healthcare Conference investment picks
2014/2/10
Proceeds support BDSI's complete execution of anticipated 2014 commercial launch plans for BUNAVAIL™ and funding of Clonidine Topical Gel NDA program RALEIGH, N.C. , Feb.
Sign-up for BioDelivery Sciences to Raise $60 Million in Registered Direct Offering From Institutional Investors investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1062429&ProfileId=051205&sourceType=1 FREDERICK, MD --
Sign-up for BioElectronics Corporation: Letter to Shareholders investment picks
2013/9/25
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0900438001&sourceType=1 http://www.ccnmatthews.com/logos/20100204-be200.jpg TORONTO, ONTARIO --
Sign-up for BioExx Announces Delisting Review Process Initiated by the Toronto Stock Exchange investment picks
2013/11/5
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0909358001&sourceType=1 http://www.ccnmatthews.com/logos/20100204-be200.jpg TORONTO, ONTARIO --
Sign-up for BioExx Announces Novel Food Status & Company Sale Process Update investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0901887001&sourceType=1 http://www.ccnmatthews.com/logos/20100204-be200.jpg TORONTO, ONTARIO --
Sign-up for BioExx Specialty Proteins Announces CCAA Filing investment picks
2013/8/29
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0895049001&sourceType=1 http://www.ccnmatthews.com/logos/20100204-be200.jpg TORONTO, ONTARIO --
Sign-up for BioExx Specialty Proteins Announces Change in Management investment picks
2014/3/27
DENVER , March 27, 2014 /PRNewswire/ --  BIOFUEL ENERGY CORP.
Sign-up for BioFuel Energy Moves To Preserve Net Operating Loss Carryforwards By Adopting Shareholder Rights Plan investment picks
2014/3/28
DENVER , March 28, 2014 /PRNewswire/ --  BIOFUEL ENERGY CORP.
Sign-up for BioFuel Energy Receives Proposal For A Possible Transaction investment picks
DENVER , Aug.
Sign-up for BioFuel Energy Reports Second Quarter 2013 Results investment picks
2013/11/11
DENVER , Nov.
Sign-up for BioFuel Energy Reports Third Quarter 2013 Results investment picks
2013/11/5
DENVER , Nov.
Sign-up for BioFuel Energy Statement On Announced Definitive Agreement investment picks
2013/11/25
DENVER , Nov.
Sign-up for BioFuel Energy Statement On Announced Sale Of Plants investment picks
2014/1/31
By Claudia Assis, MarketWatch SAN FRANCISCO (MarketWatch) -- Shares of biofuels maker Solazyme Inc. rallied 12% on Friday after the company said it started commercial operations at two facilities in Iowa, with products being sold and distributed in the U.S. and Brazil.
Sign-up for Biofuel maker Solazyme up 12%, announces commercial ops investment picks
2013/11/15
By Jacob Bunge Ethanol producers' share prices took a hit Friday after the U.S. government proposed trimming the yearly mandates for the biofuel in gasoline, raising questions about demand for a fuel source that has been a boon to the nation's farm economy.
Sign-up for Biofuel Stocks Sag As U.S. EPA Eyes Lower Ethanol Mandate investment picks
2013/11/22
By Ben Fox Rubin Biotechnology firm Biogen Idec Inc. (BIIB) said the European Medicines Agency's Committee for Medicinal Products for Human Use determined that dimethyl fumarate in its drug Tecfidera qualifies as a new active substance.
Sign-up for Biogen Gains Positive EU Determination for MS Drug; Shares Jump investment picks
2014/1/29
Biogen Idec Inc. (NASDAQ: BIIB) today reported full year and fourth quarter 2013 results, including revenue of $6.9 billion, a 26% increase compared to the prior year.
Sign-up for Biogen Idec 2013 Total Revenues Increase 26 Percent to $6.9 Billion investment picks
2013/10/28
Biogen Idec Inc.'s (BIIB) third-quarter earnings climbed 22% as sales for its multiple sclerosis treatment Tecfidera boosted the biotechnology company's revenue.
Sign-up for Biogen Idec 3rd-Quarter Profit Up 22% investment picks
2013/10/28
By Nathalie Tadena Biogen Idec Inc.'s (BIIB) third-quarter earnings climbed 22% as sales for its multiple sclerosis treatment Tecfidera boosted the biotechnology company's revenue.
Sign-up for Biogen Idec 3rd-Quarter Profit Up 22% on Tecfidera Sales, Lifts Outlook investment picks
2013/9/9
--Biogen Idec and Isis to leverage antisense technology to accelerate discovery and development of novel therapies--
Sign-up for Biogen Idec and Isis Pharmaceuticals Announce Strategic Collaboration to Advance Treatment of Neurological Disorders investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: BioDelivery Sciences Announces Submission of NDA for BUNAVAIL to Biogen Idec and Isis Pharmaceuticals Announce Strategic Collaboration to Advance Treatment of Neurological Disorders
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity